Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03267173|
Recruitment Status : Unknown
Verified August 2017 by First Affiliated Hospital of Harbin Medical University.
Recruitment status was: Recruiting
First Posted : August 30, 2017
Last Update Posted : August 30, 2017
|Condition or disease||Intervention/treatment||Phase|
|Pancreatic Cancer CAR||Drug: Chimeric antigen receptor T cell||Early Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||10 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Evaluate the Safety and Efficacy of Chimeric Antigen Receptor Engineered T Cell Immunotherapy (CAR-T) in the Treatment of Pancreatic Cancer in a Single Center, Non Controlled Clinical Study.|
|Actual Study Start Date :||June 15, 2017|
|Estimated Primary Completion Date :||June 2019|
|Estimated Study Completion Date :||June 2019|
A single dose of Chimeric antigen receptor T cells will be administered by vascular interventional mediated as one dose infusions. According to the patient's condition and weight, the intervention dose of aE7 CAR-T cells per kilogram of body weight was treated once.
Drug: Chimeric antigen receptor T cell
Evaluate the efficacy and safety of targeted Mesothelin/PSCA/CEA/HER2/MUC1/, EGFRvIII and other chimeric antigen receptor engineered T cell immunotherapy in the treatment of pancreatic cancer.
Other Name: meso-CAR
- Number of patients with tumor response [ Time Frame: 8 weeks ]Tumor response is assessmented with Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
- Number of patients with adverse event [ Time Frame: 8 weeks ]Asverse event is evaluated with CTCAE, version 4.0
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03267173
|Contact: Wei Yunwei, Dctorfirstname.lastname@example.org|
|Contact: Zhao Lei, Dctoremail@example.com|
|Harbin Medical University||Recruiting|
|Harbin, Heilongjiang, China, 150001|
|Contact: Zhao Lei, Doctor 86-13069890888 firstname.lastname@example.org|
|Study Director:||Wei Yunwei, Dctor||First Affiliated Hospital of Harbin Medical University|